AMNEAL PHARMACEUTICALS, INC. Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net of $6.44 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-07.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet · last filed 2025-05-07
- AMNEAL PHARMACEUTICALS, INC. gain (loss) on cash flow hedge ineffectiveness, net for the quarter ending 2025-03-31 was $6.44M, a 1.09% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. gain (loss) on cash flow hedge ineffectiveness, net for the quarter ending 2024-03-31 was $6.51M.
- AMNEAL PHARMACEUTICALS, INC. gain (loss) on cash flow hedge ineffectiveness, net for fiscal 2024 was $26.20M, a 678.52% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. gain (loss) on cash flow hedge ineffectiveness, net for fiscal 2023 was $3.37M.
- AMNEAL PHARMACEUTICALS, INC. gain (loss) on cash flow hedge ineffectiveness, net for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net 3 month | Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net 12 month |
|---|---|---|
| 2025-03-31 | $6.44M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $26.20M 10-K · filed 2025-02-28 | |
| 2024-03-31 | $6.51M 10-Q · filed 2025-05-07 | |
| 2023-12-31 | $3.37M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |